Global to push GA events into
skip to main content

Title: Biomarkers for liver fibrosis

Methods and systems for diagnosing or prognosing liver fibrosis in a subject are provided. In some examples, such methods and systems can include detecting liver fibrosis-related molecules in a sample obtained from the subject, comparing expression of the molecules in the sample to controls representing expression values expected in a subject who does not have liver fibrosis or who has non-progressing fibrosis, and diagnosing or prognosing liver fibrosis in the subject when differential expression of the molecules between the sample and the controls is detected. Kits for the diagnosis or prognosis of liver fibrosis in a subject are also provided which include reagents for detecting liver fibrosis related molecules.
Inventors:
; ; ; ; ;
Issue Date:
OSTI Identifier:
1357507
Assignee:
Battelle Memorial Institute PNNL
Patent Number(s):
9,651,563
Application Number:
14/799,405
Contract Number:
AC05-76RL01830
Resource Relation:
Patent File Date: 2015 Jul 14
Research Org:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES

Other works cited in this record:

Immunoassay with article having support film and immunological counterpart of analyte
patent, April 1984

Biomarkers for liver fibrosis
patent, September 2015

Advancing the High Throughput Identification of Liver Fibrosis Protein Signatures Using Multiplexed Ion Mobility Spectrometry
journal, January 2014
  • Baker, Erin Shammel; Burnum-Johnson, Kristin E.; Jacobs, Jon M.
  • Molecular & Cellular Proteomics, Vol. 13, Issue 4, p. 1119-1127
  • DOI: 10.1074/mcp.M113.034595

Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C
journal, January 2011
  • Cheung, Kin Jip; Tilleman, Kelly; Deforce, Dieter
  • European Journal of Gastroenterology & Hepatology, Vol. 23, Issue 8, p. 701-710
  • DOI: 10.1097/MEG.0b013e3283471b74

Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease
journal, September 2009
  • Bell, Lauren N.; Theodorakis, Janice L.; Vuppalanchi, Raj
  • Hepatology, Vol. 51, Issue 1, p. 111-120
  • DOI: 10.1002/hep.23271

Diagnostic accuracy of a fibrosis serum panel (FIBRO Spect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients
journal, October 2006

HepatoProteomics: Applying proteomic technologies to the study of liver function and disease
journal, January 2006
  • Diamond, Deborah L.; Proll, Sean C.; Jacobs, Jon M.
  • Hepatology, Vol. 44, Issue 2, p. 299-308
  • DOI: 10.1002/hep.21318

Noninvasive Tests for Liver Fibrosis
journal, November 2006
  • Mukherjee, Sandeep; Sorrell, Michael
  • Seminars in Liver Disease, Vol. 26, Issue 4, p. 337-347
  • DOI: 10.1055/s-2006-951598

Non-invasive assessment of chronic liver and gastric diseases
journal, May 2007

Noninvasive measures of liver fibrosis
journal, January 2006
  • Rockey, Don C.; Bissell, D. Montgomery
  • Hepatology, Vol. 43, Issue S1, p. S113-S120
  • DOI: 10.1002/hep.21046

FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy
journal, November 2007
  • Shaheen, Abdel Aziz M.; Wan, Alex F.; Myers, Robert P.
  • The American Journal of Gastroenterology, Vol. 102, Issue 11, p. 2589-2600
  • DOI: 10.1111/j.1572-0241.2007.01466.x

Similar records in DOepatents and OSTI.GOV collections: